BACKGROUND: Our goal in the present study was to investigate the prevalence and correlates of genital warts in a population of female sex workers in Mombasa, Kenya. Because of the high prevalence of human immunodeficiency virus type 1 (HIV-1) in this population, we were particularly interested in the association between HIV-1 infection and genital warts. METHODS: We conducted a cross-sectional study of the prevalence and correlates of genital warts among high-risk women in Mombasa, Kenya. Between 2001 and 2007, 1182 women were enrolled, of whom 613 (51.4%) were HIV-1 seropositive. Chi square tests and logistic regression were used to examine the associations between genital warts and potential correlates. RESULTS: Genital warts were identified on clinical examination in 27 (2.3%) women. Women who were HIV-1 seropositive were nearly 8 times as likely to have genital warts compared with HIV-1-seronegative women (odds ratio, 7.69; 95% confidence interval, 2.30-25.6). CONCLUSION: Understanding the prevalence and correlates of genital warts will help to determine whether coverage for the wart-inducing subtypes 6 and 11 in a human papillomavirus vaccine is an important consideration in resource-limited countries.
BACKGROUND: Our goal in the present study was to investigate the prevalence and correlates of genital warts in a population of female sex workers in Mombasa, Kenya. Because of the high prevalence of human immunodeficiency virus type 1 (HIV-1) in this population, we were particularly interested in the association between HIV-1 infection and genital warts. METHODS: We conducted a cross-sectional study of the prevalence and correlates of genital warts among high-risk women in Mombasa, Kenya. Between 2001 and 2007, 1182 women were enrolled, of whom 613 (51.4%) were HIV-1 seropositive. Chi square tests and logistic regression were used to examine the associations between genital warts and potential correlates. RESULTS: Genital warts were identified on clinical examination in 27 (2.3%) women. Women who were HIV-1 seropositive were nearly 8 times as likely to have genital warts compared with HIV-1-seronegative women (odds ratio, 7.69; 95% confidence interval, 2.30-25.6). CONCLUSION: Understanding the prevalence and correlates of genital warts will help to determine whether coverage for the wart-inducing subtypes 6 and 11 in a human papillomavirus vaccine is an important consideration in resource-limited countries.
Authors: G M Clifford; S Gallus; R Herrero; N Muñoz; P J F Snijders; S Vaccarella; P T H Anh; C Ferreccio; N T Hieu; E Matos; M Molano; R Rajkumar; G Ronco; S de Sanjosé; H R Shin; S Sukvirach; J O Thomas; S Tunsakul; C J L M Meijer; S Franceschi Journal: Lancet Date: 2005 Sep 17-23 Impact factor: 79.321
Authors: Michael J Silverberg; Linda Ahdieh; Alvaro Munoz; Kathryn Anastos; Robert D Burk; Susan Cu-Uvin; Ann Duerr; Ruth M Greenblatt; Robert S Klein; Stewart Massad; Howard Minkoff; Laila Muderspach; Joel Palefsky; Eva Piessens; Paula Schuman; Heather Watts; Keerti V Shah Journal: Sex Transm Dis Date: 2002-08 Impact factor: 2.830
Authors: H L Martin; P M Nyange; B A Richardson; L Lavreys; K Mandaliya; D J Jackson; J O Ndinya-Achola; J Kreiss Journal: J Infect Dis Date: 1998-10 Impact factor: 5.226
Authors: Andrea Gingelmaier; Thomas Grubert; Ralph Kaestner; Ioannis Mylonas; Tobias Weissenbacher; Florian Bergauer; Lisa Barthell; Klaus Friese Journal: Anticancer Res Date: 2007 Jul-Aug Impact factor: 2.480
Authors: J K Kreiss; N B Kiviat; F A Plummer; P L Roberts; P Waiyaki; E Ngugi; K K Holmes Journal: Sex Transm Dis Date: 1992 Jan-Feb Impact factor: 2.830
Authors: Joël Ladner; Marie-Hélène Besson; Rachel Hampshire; Lisa Tapert; Mike Chirenje; Joseph Saba Journal: BMC Public Health Date: 2012-05-23 Impact factor: 3.295
Authors: Admire Chikandiwa; Helen Kelly; Bernard Sawadogo; Jean Ngou; Pedro T Pisa; Lorna Gibson; Marie-Noelle Didelot; Nicolas Meda; Helen A Weiss; Michel Segondy; Philippe Mayaud; Sinead Delany-Moretlwe Journal: PLoS One Date: 2018-05-01 Impact factor: 3.240